Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months

Next Previous
X
Search
Trial Profile

A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 30 Aug 2023 Results of pooled analysis from NCT00514683, NCT01335464, NCT01335477, NCT01979952, NCT02999178, NCT02597933, assessing decline in forced vital capacity (FVC) as a surrogate for mortality, published in the Respirology
    • 19 May 2021 Results of pooled analysis (n=2553) assessing decline in forced vital capacity (FVC) as a surrogate for mortality from NCT00514683, NCT01335464, NCT01335477, NCT01979952, NCT02597933 and NCT02999178 trials, presented at the 117th International Conference of the American Thoracic Society.
    • 20 May 2020 Results (n=1690) of pooled analysis of five studies (TOMORROW, INPULSIS-1, 2, INMARK & NCT01979952) assessing efficacy and safety of nintedanib in patients with IPF and multiple comorbidities in < vs ≥5 comorbidities sub-groups, presented at the 116th International Conference of the American Thoracic Society.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top